MedPath

Evaluation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients on dialysis with either 2.5 or 3.0 mEq/L of dialysate calcium concentratio

Phase 4
Conditions
Maintenance hemodialysis patients with hyperphosphatemia
Registration Number
JPRN-UMIN000002820
Lead Sponsor
Rakuwakai Otowa Kinen Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1) Pts who meet the contraindiation criteria in package insert of lanthanum carbonate 2) Pregnant or possibly pregnant pts, pts on lactation 3) Inappropriate pts for this study according to the investigator's judgment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum phosphate, serum calcium and serum Ca x P product level and intact-PTH
Secondary Outcome Measures
NameTimeMethod
Adverse events, drug compliance
© Copyright 2025. All Rights Reserved by MedPath